Haleon PLC Sponsored ADR ( (HLN) ) has issued an announcement.
On January 17, 2025, Haleon PLC announced that Pfizer Inc. has reduced its stake in the company by selling 700 million ordinary shares through a secondary offering. This sale significantly decreased Pfizer’s voting rights in Haleon from 15.04% to 7.31%, impacting the company’s shareholder structure and potentially influencing its future strategic decisions.
More about Haleon PLC Sponsored ADR
Haleon PLC operates in the consumer healthcare industry, providing a range of health-focused products and services. The company is known for its market focus on over-the-counter medicinal products, offering solutions for everyday health needs.
YTD Price Performance: -2.65%
Average Trading Volume: 7,073,409
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $40.95B
Find detailed analytics on HLN stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com